BROOKS LAB LIMITED
BROOKS · General/Diversified · NSE
₹67
Current Market Price
Fair Value (DCF)
₹52
Margin of Safety
-22.1%
Updated 1d ago
YieldIQ Score
46/100
Piotroski F-Score
6/9
Economic Moat
Narrow
Confidence
24%
ROE
—
Debt/Equity
0.07
WACC
11.1%
Market Cap
₹198 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
—
Return on capital employed
EV / EBITDA
25.1×
Enterprise multiple
Debt / EBITDA
1.0×
Leverage vs earnings
Interest Coverage
-10.5×
EBIT covers interest
Current Ratio
1.48×
Short-term liquidity
Asset Turnover
0.66×
Revenue per ₹ of assets
Revenue CAGR (3Y)
-3.0%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹67.1
Bear case
₹31.32
MoS -114.2%
Base case
₹52.3
MoS -28.3%
Bull case
₹64.78
MoS -3.6%
Ratio Trends
BROOKS · last 4 annual periods
ROE
-10.2%
ROCE
-6.9%
Operating Margin
—
Debt / Equity
0.08×
PE
—
EV / EBITDA
—
Historical Financials
BROOKS · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹77.2 Cr | ₹91.1 Cr | ₹55.5 Cr | ₹79.5 Cr | ₹82.2 Cr | +1.6% |
| EBITDA | — | ₹-13.7 Cr | ₹-29.4 Cr | ₹-17.1 Cr | ₹-7.3 Cr | — |
| EBIT | ₹-5.9 Cr | ₹-20.8 Cr | ₹-7.4 Cr | ₹2.4 Cr | — | — |
| PAT | ₹-19.4 Cr | ₹-19.3 Cr | ₹-8.2 Cr | ₹-19.6 Cr | ₹-10.0 Cr | — |
| EPS (diluted) | ₹6.31 | ₹-7.82 | ₹3.32 | ₹-7.67 | — | — |
| CFO | ₹4.5 Cr | ₹-37.4 Cr | ₹0.6 Cr | ₹-9.7 Cr | ₹2.5 Cr | -13.3% |
| CapEx | — | — | — | — | ₹-0.9 Cr | — |
| FCF | — | — | — | — | ₹1.6 Cr | +0.0% |
| Total Assets | — | ₹196 Cr | ₹92.4 Cr | ₹90.4 Cr | ₹124 Cr | -10.9% |
| Total Debt | — | — | ₹5.7 Cr | ₹5.0 Cr | ₹7.6 Cr | +7.6% |
| Shareholders' Equity | — | — | ₹56.8 Cr | ₹65.6 Cr | ₹98.1 Cr | +14.7% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
BROOKS vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| NATCAPSUQ NATCAPSUQ | — | — | Pending | 0.2% | — |
| AAREYDRUGS AAREYDRUGS | — | — | Pending | 2.9% | — |
| NECLIFE NECLIFE | — | — | Pending | -11.9% | — |
| ALPA ALPA LABORATORIES LTD | +6.2% | 33 | Near Fair Value | 11.4% | — |
| KREBSBIO KREBS BIOCHEMICALS & IND | -100.0% | 33 | Data Limited | 18.4% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for BROOKS in the last 10 years.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. BROOKS LAB LIMITED (BROOKS.NS) trades at 67.10 vs a model fair value of 52.30, a gap of -22.1%. Piotroski F-score: 6/9. Moat label: Narro...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of BROOKS →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for BROOKS →
Compare
Head-to-head with peers
Compare BROOKS side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse BROOKSNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.